Expanded Access Program for a Multicentre, Open, Non Randomized Study, Evaluating Safety of Erythrocytes Encapsulating L-asparaginase (GRASPA(R)) in Combination With Polychemotherapy in Patients Under 55 Years Old With Acute Lymphoblastic Leukemia (ALL) at Risk to Receive Other Formulation of Asparaginase

Trial Profile

Expanded Access Program for a Multicentre, Open, Non Randomized Study, Evaluating Safety of Erythrocytes Encapsulating L-asparaginase (GRASPA(R)) in Combination With Polychemotherapy in Patients Under 55 Years Old With Acute Lymphoblastic Leukemia (ALL) at Risk to Receive Other Formulation of Asparaginase

Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 15 Jul 2017

At a glance

  • Drugs ERY-ASP (Primary)
  • Indications Acute lymphoblastic leukaemia
  • Focus Adverse reactions; Expanded access
  • Acronyms EAP
  • Sponsors ERYtech Pharma
  • Most Recent Events

    • 05 May 2015 According to an ERYtech Pharma media release, an independent Data and Safety Monitoring Board (DSMB) completed its first safety assessment of this program and recommended continuation of the program without modification.
    • 07 Nov 2014 Initial results to be presented at the 56th Annual Meeting and Exposition of the American Society of Hematology, according to an ERYtech Pharma media release.
    • 31 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top